Cinacalet, introduced to the market in 2004, is a positive allosteric modulator of CaS calcium-sensing receptor, which is used to treat secondary hyperparathyroidism (elevated parathyroid hormone levels) as it blocks the secretion of parathyroid hormone [15]. The gene discussed is PTH; the disease is secondary hyperparathyroidism.